# Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

> **NCT05795244** · PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 30 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Endometrial Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05795244
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795244, "Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05795244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*